News - Psilocybin Alpha

New Resource: Psychedelic Legalization & Decriminalization Tracker

Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using Kernel Flow Technology

Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using Kernel Flow Technology

Post published:October 26, 2021
Post category:Press Release

MindMed Announces R(-)-MDMA Program to target Social Anxiety Associated with Autism Spectrum Disorder

MindMed Announces R(-)-MDMA Program to target Social Anxiety Associated with Autism Spectrum Disorder

Post published:October 26, 2021
Post category:Press Release

HAVN Life Announces Departure of Rick Brar as Director

HAVN Life Announces Departure of Rick Brar as Director

Post published:October 25, 2021
Post category:Press Release

Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific & Strategic Advisory Board

Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific & Strategic Advisory Board

Post published:October 25, 2021
Post category:Press Release

European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the Treatment of Depressive Disorders

European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the Treatment of Depressive Disorders

Post published:October 25, 2021
Post category:Press Release

MindMed CMO to Chair Digital Biomarkers Summit

MindMed CMO to Chair Digital Biomarkers Summit

Post published:October 25, 2021
Post category:Press Release

Beckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial Assessing Safety and Tolerability of Intranasal 5-MeO-DMT

Beckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial Assessing Safety and Tolerability of Intranasal 5-MeO-DMT

Post published:October 25, 2021
Post category:Press Release

Psychedelic Bulletin: Small Pharma Secures Fast-Track Designation in UK; Boris Johnson to Consider Rescheduling Psilocybin; COMPASS Reports Psilocybin Group Therapy Data

Psychedelic Bulletin: Small Pharma Secures Fast-Track Designation in UK; Boris Johnson to Consider Rescheduling Psilocybin; COMPASS Reports Psilocybin Group Therapy Data

Post published:October 22, 2021
Post category:Psychedelic Investment Bulletin

Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder

Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder

Post published:October 21, 2021
Post category:Press Release

Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product

Post published:October 20, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.